HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NA | Raloxifene Hydrochloride | Evista | 60 mg | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Yes | 1997 | In Use | ||||
NA | Ripretinib | Qinlock | 50mg | Chemotherapy | Tyrosine Kinase Inhibitor | KIT, PDGFRA | Yes | 2020 | In Use | |||
NA | Rucaparib | Rubraca | 200 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2017 | In Use | |||
NA | Ruxolitinib | Jakafi | 5 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
NA | Selinexor | Xpovio | 20mg, 40mg, 50mg, 60mg | Chemotherapy | Enzyme Inhibitor | XPO1 | Yes | 2019 | In Use | |||
NA | Selpercatinib | Retevmo | 40mg, 80mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2020 | In Use | |||
NA | Selumetinib | Koselugo | 10mg, 25mg | Chemotherapy | MEK Inhibitor | MEK 1/2 | Yes | 2020 | In Use | |||
NA | Sorafenib | Nexavar | 200 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR,KIT,RET, CRAF, BRAF | Yes | 2005 | In Use | |||
NA | Sotorasib | Lumakras | Multiple | Chemotherapy | RAS Inhibitor | KRASG12C | Yes | 2021 | In Use | |||
NA | Tepotinib Hydrochloride | Tepmetko | 225mg | Chemotherapy | Tyrosine Kinase Inhibitor | MET | Yes | 2021 | In Use | |||
NA | Testolactone | Teslac | 250 mg | Hormonal Therapy | Androgen | Yes | 1970 | Jun 25, 2005 | No Longer Used | |||
NA | Thioguanine | Tabloid | 40 mg | Chemotherapy | Antimetabolite | Purine Analog | Yes | 1966 | In Use | |||
Not yet assigned | Tisagenlecleucel | Kymriah | consult labeling | Immunotherapy | CAR-T | CD19 | No | 2017 | In Use | |||
NA | Capmatinib | Tabrecta | 150mg, 200mg | Chemotherapy | Tyrosine Kinase Inhibitor | MET | Yes | 2020 | In Use | |||
NA | Estrogens, Esterified | Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est | 0.625 mg | Hormonal Therapy | Estrogen | Yes | 1977 | In Use | ||||
NA | Tivozanib | Fotivda | 0.89mg, 1.34mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2021 | In Use | |||
NA | Toremifene Citrate | Fareston | 60 mg | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Yes | 1997 | In Use | ||||
NA | Trametinib | Mekinist | 0.5 mg | Chemotherapy | MEK Inhibitor | BRAF | Yes | 2013 | In Use | |||
NA | Trametinib | Mekinist | 2 mg | Chemotherapy | MEK Inhibitor | BRAF | Yes | 2013 | In Use | |||
NA | Trifluridine and Tipiracil | Lonsurf | 20/ 8.19 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | Yes | 2015 | In Use | |||
NA | Trifluridine and Tipiracil | Lonsurf | 15/6.14 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | Yes | 2015 | In Use | |||
NA | Trilostane | Modrastane | 60 mg, 120 mg | Hormonal Therapy | Adrenocortical suppressant | Yes | 1984 | 1994 | In Use | |||
NA | Tucatinib | Tukysa | 50mg,150mg | Chemotherapy | Tyrosine Kinase Inhibitor | HER2 | Yes | 2020 | In Use | |||
NA | Uridine Triacetate | Vistogard | 10 g | Ancillary Therapy | Chemoprotective | Antidote | Yes | 2015 | In Use | |||
Momelotinib | Ojjaara | Multiple | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2023 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.